Skeletal muscle expressing Pro104Leu mutant caveolin 3 (CAV3 P104L ) in mouse becomes atrophied and serves as a model of autosomal dominant limb-girdle muscular dystrophy 1C. We previously found that caveolin 3-deficient muscles showed activated intramuscular transforming growth factor beta (TGF-b) signals. However, the cellular mechanism by which loss of caveolin 3 leads to muscle atrophy is unknown. Recently, several small-molecule inhibitors of TGF-b type I receptor (TbRI) kinase have been developed as molecular-targeting drugs for cancer therapy by suppressing intracellular TGF-b1, -b2, and -b3 signaling. Here, we show that a TbRI kinase inhibitor, Ki26894, restores impaired myoblast differentiation in vitro caused by activin, myostatin, and TGF-b1, as well as CAV3
Muscle atrophy impairs the activities of daily living and is implicated in fatal outcomes in various diseases, including muscular dystrophy and cancer. 1, 2 Recently, a growing number of transcription factors, membrane and cytoskeletal proteins, and cytokines have been found to participate in the molecular mechanisms leading to muscle atrophy, including caveolin 3 and myostatin. [3] [4] [5] [6] [7] [8] Caveolin 3, a muscle-specific integral membrane protein, forms flask-shaped invaginations of the plasma membrane known as caveolae, and regulates signal transduction pathways by binding specific lipid-modified signal molecules, including Ha-Ras, G protein-coupled receptors, Srk-family kinases, and nitric oxide synthases. 9 Loss of caveolin 3 resulting from dominant-negative mutations in the CAV3 gene causes autosomal dominant limb-girdle muscular dystrophy (LGMD) 1C. 9, 10 We previously developed a transgenic mouse overexpressing Pro104Leu mutant caveolin 3 (CAV3 P104L ) as a model of LGMD1C; these mice demonstrated myopathy characterized by muscle atrophy. 11 We found that the caveolin 3-deficient muscles in the transgenic mice showed activation of intramuscular transforming growth factor beta (TGF-b)-mediated signals, including myostatin, which is specifically expressed in skeletal muscle and negatively regulates muscle mass and growth. [5] [6] [7] [8] However, the cellular pathobiology leading to muscle atrophy caused by the loss of caveolin 3 and activated intramuscular TGF-b signals remains to be elucidated.
Small-molecule compounds to antagonize TGF-b signals at membrane receptor serine/threonine kinases have recently been proposed as molecular-targeted drugs for cancer therapy. 12 Tumor cells in advanced stages become refractory to TGF-b-induced growth arrest, but often overexpress TGF-b1, -b2, and -b3. 13 TGF-b family members induce the epithelialmesenchymal transition, immunosuppression, and angiogenesis, resulting in tumor growth and metastasis. Each member of the TGF-b family binds to a membrane serine/ threonine kinase receptor, termed as a type II receptor, which then recruits a type I kinase receptor. 1, 14 Seven different type I receptors, the activin receptor-like kinases 1-7 (ALK1-7), thus determine the intracellular signal specificity of the 33 members of the TGF-b family. 1, 14 Small-molecule inhibitors of TGF-b type I receptor (TbRI) kinase were originally developed to compete with the binding of adenosine triphosphate to the kinase domain of ALK5, the type I receptor for TGF-b1-3. 12 TbRI kinase inhibitors have been found to suppress tumor enlargement and metastasis in the advanced stages of cancer in animals. [15] [16] [17] [18] Notably, these inhibitors also suppress a similar kinase domain of ALK4, the type I receptor for activin, and potentially block ALK4/5, the type I receptor for myostatin. 1, 12, 19, 20 However, the impact and clinical significance of TbRI kinase inhibitors on the skeletal muscle signaling of activin, myostatin, and TGF-b1-3 is unknown.
Considering the potential broad suppression profile of TbRI kinase inhibitors on the multiple intramuscular TGF-b signals, we postulated that these inhibitors could be used as optimal probes to explore the cellular mechanisms of how activated intramuscular TGF-b signals lead to muscle atrophy in caveolin 3-deficient muscular dystrophy. Alternatively, by suppressing the multiple anti-myogenic TGF-b signals, pharmacological intervention using this type of inhibitor would be expected to prevent muscle atrophy in caveolin 3-deficient mice. In the current study, we tested our hypothesis by examining the effects of TbRI kinase inhibitors on myogenesis via muscle precursor satellite cells, as well as myoblasts. The ability of an oral inhibitor to increase muscle mass, or to slow the progression of atrophy and weakness was further investigated in wild-type or caveolin 3-deficient mice, to investigate its potential in the future treatment of patients with muscular atrophy.
MATERIALS AND METHODS Cell Lines and Reagents
A204 human rhabdomyosarcoma cells, HEK293 human embryonic kidney cells, and HaCaT human keratinocytes were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 0.1 mM non-essential amino acids, and 50 mg/ml kanamycin. The pGL3-(CAGA) 12 -luciferase reporter containing the TGF-b-sensitive Smad-binding sequence (CAGA) was kindly provided by Dr C-H Heldin (Uppsala University, Sweden). 21 Recombinant myostatin, activin A, and TGF-b1 (R&D Systems, Minneapolis, MN, USA) were prepared as 100 mg/ml stock solutions in 0.1% bovine serum albumin with 4 mM HCl. The small-molecule TbRI kinase inhibitors, Ki26894 (FW 374.40; Kyowa Hakko Kirin, Nagaizumi, Shizuoka, Japan), SB-431542 (FW 420.42; Sigma-Aldrich, St Louis, MO, USA), and LY-364947 (FW 327.30; Chemicon, Temecula, CA, USA) were dissolved and serially diluted from 10 mM to 1 mM in dimethyl sulfoxide as 1000-fold concentrated solutions. C2C12 myoblasts were maintained in growth medium comprising DMEM plus 10% FBS. The pMXs-IRES-GFP retroviral vector and the Plat-E packaging cells, and the antibody raised against M-cadherin, also known as cadherin 15 (CDH15), for satellite cell analysis, were kind gifts from T Kitamura (Institute of Medical Science, The University of Tokyo, Japan), and Drs Y Miyagoe-Suzuki and S-I Takeda (National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan), respectively.
Luciferase Assays A204 cells or HEK293 cells were seeded on 12-well plates at 1.0 Â 10 5 cells/well and maintained for 24 h, respectively. These cells were then co-transfected with the pGL3-(CAGA) 12 -luciferase reporter gene. After 24 h, the medium was replaced with DMEM containing 10 ng/ml recombinant myostatin, 10 ng/ml activin A, or 6 ng/ml TGF-b1. The TbRI kinase inhibitors, Ki26894, SB-431542, or LY-364947 were also added to the culture medium. After an additional 24 h, cells were lysed with 1 Â lysis buffer (Promega, Madison, WI, USA) and luciferase activity in the cell lysates was determined by a luciferase reporter assay system (Promega) using a MiniLumat LB 9506 luminometer (EG&G Berthold, Nashua, NH, USA) and was normalized to b-galactosidase activity. For the ex-vivo myostatin bioassay, sera from mice fed without or with Ki26894 were diluted four-fold (to 25%) with DMEM containing 10 ng/ml recombinant myostatin. The resulting mixture was added to HEK293 cells co-transfected with the pGL3-(CAGA) 12 -luciferase reporter gene and pCMV-b-Gal.
In-Vitro Expression Assay for p21 and p15
HaCaT human keratinocyte cells were seeded in 10-cm dishes at 1.0 Â 10 6 cells/dish and maintained for 24 h, followed by incubation in serum-free medium for 2 h. The cells were then incubated with or without Ki26894 plus 10 ng/ml recombinant myostatin, 10 ng/ml activin A, or 6 ng/ml TGF-b1. Cellular RNA was extracted at the indicated times and the gene expression of p21, also known as cyclin-dependent kinase inhibitor (Cdkn) 1a, and p15, also known as Cdkn1b, was examined by northern blotting.
Construction of Retroviral Vectors
Mouse cDNAs for myostatin, activin A, and TGF-b1 were cloned into retroviral vectors. The NcoI-SalI fragment of green fluorescent protein (GFP) cDNA in the original pMXs-IRES-GFP retroviral vector 22 was substituted with the Cherry cDNA fragment derived from the pmCherry-N1 plasmid vector (Clontech, Mountain View, CA, USA). One microgram of total RNA from mouse skeletal muscle was reverse transcribed with an oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and subjected to PCR using the following primers: myostatin, 5
0 -CGGGATC-CATGATGCAAAAACTG-3 0 and 5
0 -CGGAATTCATGCCGCCCTCGGGG-3 0 and 5 0 -CGCTCGAGTCAGCTGCACTTGC-3 0 . The resulting PCR products were then cloned into the pMXs-IRES-Cherry vector using the appropriate restriction sites. The cDNA fragments of the Pro104Leu mutant caveolin 3 (ref. 5) were also ligated to the original vector.
In-Vitro Myogenic Differentiation Assays
Using the above retroviral vectors, we generated C2C12 cells expressing TGF-b family members, or Pro104Leu mutant caveolin 3, according to a method previously described. 22 Briefly, C2C12 myoblasts were maintained in growth medium comprising DMEM plus 10% FBS. Myogenic differentiation was initiated by placing 60% confluent cultures in differentiation medium comprising DMEM plus 2% horse serum with or without 10 nM Ki26894. Retrovirus vectors expressing TGF-b family members or mutant caveolin 3 were then transfected into Plat-E packaging cells. Supernatants containing retrovirus were passed through 0.45 mm filters. C2C12 cells were infected with the filtrates for 6 h and the medium was then replaced with differentiation medium. For immunocytochemical analysis, the cells were fixed and stained with anti-myosin heavy chain (MyHC) monoclonal antibody (mAb) (MY-32; Sigma-Aldrich), anti-muscle creatine kinase-M polyclonal antibody (N-13; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or anti-myogenin mAb (F5D; Santa Cruz Biotechnology), followed by Alexa 488-conjugated anti-mouse or anti-goat IgG antibody (Invitrogen, Carlsbad, CA, USA). Lysates from C2C12 cells were resolved by SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane. Immunoblot analysis was performed using MY-32.
Fusion Indices
The number of nuclei in mononucleated cells and myotubes defined as syncytia containing 43 nuclei were counted in four independent fields of 1 mm 2 (n ¼ 5). The fusion indices were calculated as ratios (%) of the total number of nuclei incorporated in myotubes.
Animals and Administration of Ki26894
Transgenic mice overexpressing the LGMD1C-causing Pro104Leu mutant caveolin 3 (CAV3 P104L ) 9 under the control of 6.5 kb of the muscle creatinine kinase (MCK) gene promoter/enhancer sequences, including 3.3 kb upstream of exon 1, the complete intron 1 and exon 2 truncated just 5 0 of the initiator methionine, were generated previously. 11 These mice demonstrated myopathy characterized by muscle atrophy and loss of caveolin-3, with increased intramuscular TGF-b signal. 5, 6, 11 Ki26894 was mixed with normal powdered food (CE-2; CLEA, Hamamatsu, Shizuoka, Japan) to a final concentration of 0.08%, and was orally administered to caveolin 3-deficient transgenic mice (CAV3 P104L ) or control wild-type mice aged between 6 and 16 weeks, as described. 18 All animal experiments were performed at the Laboratory Animal Center and were approved by the Animal Research Committee of Kawasaki Medical School.
Immunohistochemical and Morphometric Analyses
Frozen quadriceps femoris muscles were transversely sectioned at the center of the muscles. The sections were fixed and stained using the anti-rat laminin a2 mAb (4H8-2; Sigma-Aldrich) followed by Alexa 488-conjugated anti-rat IgG antibody (Invitrogen). The areas of single myofibers in the quadriceps muscles (n ¼ 20; 250 myofibers per mouse) were measured on fluorescence images of laminin a2-stained sections using the two-color technique, as previously described. 5 To detect infiltration of inflammatory cells in muscles, sections were stained with a rat anti-mouse CD11b mAb (BD Pharmingen, San Diego, CA, USA).
For satellite cell analysis, the sections were stained with an anti-rabbit M-cadherin polyclonal antibody raised against the carboxyl-terminal region of mouse M-cadherin (Invitrogen) and an anti-rat laminin a2 mAb 4H8-2 (Sigma-Aldrich) followed by Alexa 488-conjugated antirabbit IgG and Alexa 594-conjugated anti-rat IgG Abs (Invitrogen). Myonuclei were post-stained with 4 0 ,6-diamidino-2-phenylindole, DAPI (Vector Laboratories, Burlingame, CA, USA). The findings were confirmed using another anti-rabbit M-cadherin polyclonal antibody raised against amino acids 399-444 of mouse M-cadherin, as shown in Supplementary Figure 7 .
Isolation of Single Myofiber and Attached Satellite Cells
We isolated single myofibers from the extensor digitorum longus (EDL) muscles of mice aged 16 weeks according to a previously described method. 23 Briefly, EDL muscles were digested in freshly prepared 0.5% type I collagenase (Worthington Laboratories, Freehold, NJ, USA) in DMEM. After gentle sucking of these muscle digests in and out of a widebore flame-polished Pasteur pipette, a single myofiber was isolated and placed individually on a coverslip precoated with 1 mg/ml Matrigel (BD Bioscience, San Jose, CA, USA). The single myofiber was fixed with 4% paraformaldehyde in PBS and stained with a rabbit anti-mouse caveolin-1 pAb (BD Transduction Laboratories, Lexington, KY, USA), an anti-mouse caveolin-3 mAb (Santa Cruz), and an anti-mouse Pax7 mAb (GT), followed by labeling with Alexa 488-conjugated anti-rabbit and Alexa Fluor 594-conjugated anti-mouse IgG antibodies (Molecular Probe). Nuclei were post-stained with DAPI. Immunofluorescence images were captured using a laser scanning confocal microscope (TCS SP2; Leica Microsystems, Wetzlar, Germany) or a fully motorized inverse microscope (IX81, Olympus, Tokyo, Japan).
Vital Staining of Damaged Myofibers
To detect damaged myofibers, Evans Blue dye (EBD, 20 mg/ ml in PBS) was injected into mice (0.15 ml/10 g body weight) intraperitoneally, basically according to a previously described method. 24 Mice were killed 24 h after injections. Skeletal muscles were sectioned and fluorescence images were evaluated under a fully motorized inverse microscope.
Muscle Performance
Mice grasping a wire mesh with their limbs were pulled horizontally by their tail until they lost their grip. Peak grip strength (g) was measured using an MK-380S automated Grip Strength Meter (Muromachi, Tokyo, Japan). The tetanic force of the tibialis anterior (TA) or diaphragm of mice at 16 weeks of age was measured essentially as previously described. 25 Briefly, the TA or diaphragm was quickly excised and the peripheral tendons were secured with a 5-0 silk suture. Both ends of the muscle were fixed using a tissue clamp (B-small; Natsume, Tokyo, Japan). The muscle was vertically mounted in a chamber that was perfused with oxygen-saturated Ringer's solution and maintained at 25 1C. The muscle was then connected to a UL-50GR force transducer (Minebea), and an MM-3 length servosystem (Narishige, Tokyo, Japan). The muscle was stimulated through a pair of platinum plates attached at both sides of the chamber using an SEN-3401 electronic stimulator (Nihon Kohden, Tokyo, Japan). Tetanic force was recorded and analyzed using a PowerLab system and LabChart v6 software (ADInstruments, Colorado Springs, CO, USA). The length of the muscle fibers was incrementally adjusted using a micropositioner until the maximal twitch force response was obtained (optimal fiber length). The maximal tetanic force was assessed at a stimulation frequency of 150 Hz delivered in 1000 ms trains with 2 min intervals between trains. After obtaining three measurements, the attached bone and sutures were removed and the muscle was weighed. The muscle crosssectional area was calculated using the formula: muscle wet weight (in mg)/optimal fiber length (in mm) Â 1.056 (in mg/mm 3 ). Specific tetanic forces (maximal tetanic force/ cross-sectional area) of the muscle were determined using the estimated cross-sectional area.
RT-PCR and Northern Blotting
Total RNAs from mouse skeletal muscle or HaCaT cells were fractionated on northern gels, and probed with labeled cDNAs for mouse p21 (nucleotides (nt) 1-255), mouse p15 (nt 32-385), mouse 18S rRNA (nt 1-453), human p21 (nt 1-255), or human p15 (nt 508-921).
Smad2 Phosphorylation Analysis
Skeletal muscle from 16-week-old mice was homogenized in 10 volumes (w/v) of a buffer consisting of 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, 5 mM b-mercaptoethanol, 0.1 mM PMSF, and 1 mM benzamidine. The crude extracts were resolved by SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. Immunoblot analysis was performed using rabbit anti-mouse Smad2 or phosphorylated Smad2 (p-Smad2) (Ser465/467) antibodies (Cell Signaling Technology, Danvers, MA, USA).
Statistics
Paired observations were statistically analyzed using one-way analysis of variance followed by Bonferroni's test. P-values o0.05 were considered statistically significant.
RESULTS

TbRI Kinase Inhibitors Broadly Suppress the In-Vitro Transcriptional Activities of TGF-b Family Members
To investigate whether TbRI kinase inhibitors can suppress TGF-b signals other than TGF-b1-3 in vitro, we tested three inhibitors: SB-431542, LY-364947, and Ki26894.
17-20 A204 human rhabdomyosarcoma cells or HEK293 human embryonic kidney cells were transfected with pGL3-(CAGA) 12 luciferase, a TGF-b-sensitive Smad-responsive luciferase reporter gene. 21 Stimulation of these cells with recombinant myostatin, activin A, or TGF-b1 caused a significant increase in luciferase activity above the basal level (A204: Figure 1a-c; HEK293: Figure 1d -f). The addition of an individual inhibitor to the culture media suppressed luciferase activity in a dosedependent manner. The intracellular signal specificity of myostatin, activin A, or TGF-b1 is determined by the recruitment of ALK4/5.
1 Thus, these TbRI kinase inhibitors can suppress the intracellular signaling of myostatin through ALK4/5, activin A through ALK4, and TGF-b1 through ALK5. In A204 cells, the three inhibitors suppressed myostatin, activin A, or TGF-b1 comparably, whereas in HEK293 cells, Ki26894 inhibited myostatin B15-fold more potently than either SB-431542 or LY-364947 with half-maximal inhibitory concentration values of 7, 100, and 100 nM, respectively. We selected Ki26894 as a representative inhibitor for subsequent experiments.
We further investigated the effects of Ki26894 on TGF-binduced gene expression of the cyclin-dependent kinase (CDK) inhibitors, p21 and p15 in HaCaT human keratinocyte cells, a cell line in which the intracellular signaling pathways activated by different members of the TGF-b family have been characterized in detail. 26 Myostatin time dependently induced the expression of p21, but not of p15, while Ki26894 suppressed p21 upregulation (Figure 1d ). Ki26894 also blocked p21 expression induced by activin A and TGFb1. Thus, this TbRI kinase inhibitor suppressed the common intracellular signal pathways leading to p21 upregulation that are induced by the different members of the TGF-b family.
Ki26894 Reverses Impaired Myoblast Differentiation
In Vitro Caused by TGF-b1, Activin, and Myostatin Myostatin suppresses the differentiation of C2C12 myoblasts exposed to low-serum conditions. 27 Using an efficient retrovirus-mediated gene transfer system, 22 we assessed the effect of Ki26894 on the differentiation of C2C12 myoblasts expressing TGF-b1 or activin A, as well as myostatin. Transferring C2C12 myoblasts expressing an empty vector from high-serum (growth) to low-serum (differentiation) media caused them to fuse and form multinucleated myotubes. We then stained the cells with antibodies against MyHC, myogenin, and creatine kinase (CK), and measured the fusion indices (Figure 2a-c) . Adding Ki26894 to the culture media enhanced myoblast fusion and myotube formation. On the other hand, myotube formation was impaired in C2C12 myoblasts expressing myostatin, activin A, or TGF-b1, compared with controls harboring an empty vector (Figure 2d and e). Notably, Ki26894 reversed the impaired myotube formation induced by these TGF-b family members. Immunoblotting analyses showed that Ki26894 restored the reduced protein expression of MyHC in C2C12 myoblasts. These findings indicate that TbRI kinase inhibitors enhance myoblast differentiation in vitro by suppressing the activity of several members of the anti-myogenic TGF-b family members, including activin, or TGF-b1, as well as myostatin.
Ki26894 Reverses Reduced Myotube Formation by Forced Expression of Pro104Leu Mutant Caveolin 3
We previously showed that caveolin 3 binds and suppresses ALK4/5 in COS7 monkey kidney cells by forced expression of these molecules using plasmid vectors. 5 Moreover, other groups have reported that expression of a CAV3 antisense RNA, or a Pro104Leu dominant-negative mutant CAV3 cDNA suppressed the differentiation of C2C12 myoblasts into myotubes under low-serum conditions. 28, 29 We thus expressed the Pro104Leu dominant-negative mutant CAV3 cDNA in C2C12 cells using the above retroviral system, to explore the molecular significance of caveolin 3 and TGF-b signals in myoblast differentiation. Similarly to the results of the TGF-b expression, myotube formation was impaired in C2C12 myoblasts overexpressing Pro104Leu mutant caveolin 3, compared with controls (Figure 3a-c) . Importantly, Ki26894 reversed the impaired myotube formation induced by the mutant caveolin 3. TbRI kinase inhibitors thus could reverse myotube formation by suppressing the enhanced intracellular TGF-b signals resulting from a dominant-negative caveolin 3 mutation.
Administration of an Oral TbRI Kinase Inhibitor Enhances Myogenesis In Vivo in Wild-Type Mice
Before starting systemic administration of Ki26894, we determined its bioavailability against myostatin activity using an ex-vivo bioassay system. Ki26894 was orally administered in the food to 10-week-old wild-type mice as previously described. 18 Sera from 12-week-old wild-type mice fed with or without Ki26894 for 2 weeks were added to the culture media of HEK293 cells transfected with a luciferase reporter gene (n ¼ 10; Supplementary Figure 1) . Recombinant myostatin-induced luciferase activity was decreased to 19% by adding sera from Ki26894-fed mice to the culture media to a final concentration of 25%. Thus, the sera in physiological conditions (50% in blood) should completely suppress myostatin activity. Therefore, we administered Ki26894 orally to the mice at a concentration of 0.08% in their food.
Ki26894 was orally administered in powdered food to wild-type mice starting at 6 weeks of age. The body weight of the mice fed with or without Ki26894 was monitored until 16 weeks, when the mice were killed for further analysis. Body weight, peak grip strength force, muscle weight, and single myofiber area (SMA) were larger in mice fed with Ki26894 compared with those not fed with Ki26894, suggesting enhanced myogenesis in vivo (Supplementary Figure 2) .
Oral Administration of Ki26894 Rescues Muscle Atrophy in Caveolin 3-Deficient Mice
We next administered Ki26894 to an atrophic caveolin 3-deficient muscular dystrophy model mouse (CAV3 P104L ), because we previously demonstrated that elevated intramuscular TGF-b signals led to muscle atrophy in these mice. 5 The mice fed with Ki26894 from 9-10 to 16 weeks of age were significantly heavier than those that did not receive Ki26894 (n ¼ 20; Figure 4a ). We did not detect any adverse effects in the mice fed with Ki26894 at any time point until 16 weeks, and no significant pathological abnormalities were found at the end of the experiments, including in the ovary where suppression of activin was reported to cause a reproductive defect 30 (Supplementary Figure 6) . The observation of skinned hind-limb muscles showed that Ki26894 ameliorated muscle atrophy compared with the muscles of untreated mice ( Figure  4b ). Ki26894 also increased muscle weight in CAV3 P104L mice (Figure 4c ). At 16 weeks of age, H&E-stained sections of quadriceps femoris muscles from both CAV3 P104L and wildtype mice were examined. As we reported previously, 5, 11 
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P104L mouse muscle (Figure 4d , upper) showed marked reduction of myofiber size, compared with wild-type mouse muscle (Figure 4d, lower) Figure 4e) . Consistently, the SMA in Ki-treated wild-type mice was also significantly increased compared with that in untreated wild-type mice (males, 3779.1±762.9 vs 2937.7±607.7 mm 2 ; females, 3389.8 ± 756.5 vs 2685.4 ± 746.5 mm 2 ; both Po0.05; Supplementary  Figure 2) . Thus, long-term administration of Ki26894 induces postnatal myofiber hypertrophy as shown by the increase in mean SMA in CAV3 P104L mice (males, Â 1.48; females, Â 1.42) and wild-type mice (males, Â 1.28; females, Â 1.26).
We further examined the effects of Ki26894 on muscle histology other than myofiber size, including the number of EBD-positive necrotic myofibers ( Supplementary  Figure 3) , infiltration of CD11b-positive inflammatory cells (Supplementary Figure 4a) and Masson's trichrome-positive fibrous tissue replacement (Supplementary Figure 4b) , and the number of centrally nucleated regenerative myofibers (Supplementary Figure 5) . These changes were far less common in CAV3 P104L mice than in dystrophin-deficient mouse muscles, suggesting an increase in the amount of muscle regeneration induced by Ki26894. Peak grip strength force was also greater in Ki26894-treated mice than in untreated mice (n ¼ 20; Figure 5a ). As ex- pected, the specific force of the TA or diaphragm muscles was significantly lower in CAV3 P104L mice than in wild-type mice (n ¼ 7; Figure 5b ). Oral Ki26894 increased muscle-specific force both in CAV3 P104L mice and in wild-type mice. We also found that serum myostatin activity was significantly reduced in Ki26894-treated CAV3 P104L mice compared with that in untreated mice at 15 weeks of age (Figure 5c ).
Ki26894 Decreases the Intramuscular TGF-b Signal and Increases the Number of Satellite Cells In Vivo
To investigate the intramuscular TGF-b signal, we examined the levels of p-Smad2, its intracellular effector, in crude muscle homogenates (n ¼ 7; Figure 5d ). The amounts of total Smad2 protein were comparable in wild-type and CAV3 P104L mice, with or without Ki treatment, whereas the level of p-Smad2 was significant increased in CAV3 P104L mice compared with wild-type mice. Ki treatment significantly reduced p-Smad2 levels in both lines of mice. We further investigated the expression of p21 and p15 in the skeletal muscle of CAV3 P104L mice to determine the effects of Ki26894 on intramuscular signaling (n ¼ 7; Figure 5e ). The mRNA expression of p21 was increased in CAV3 P104L mice compared with wild-type mice, suggesting enhanced intramuscular TGF-b signaling caused by loss of caveolin 3. Importantly, oral Ki26894 administration decreased p21 expression in both wild-type and CAV3 P104L mice. In contrast, p15 expression was not affected by oral administration of Ki26894. These results are consistent with our in-vitro findings that TbRI kinase inhibitors suppress intracellular signaling pathways activated by members of the anti-myogenic TGF-b family.
Muscle precursor satellite cells reside beneath the basal lamina of the myofibers, where they have important roles in postnatal muscle growth as resident stem cells in adult skeletal muscle. 31 We evaluated satellite cells in the quadriceps femoris muscles of CAV3 P104L mice compared with wild-type mice by immunostaining for the marker protein M-cadherin. At both time points (6, 10, or 24 weeks of age), the number of M-cadherin-positive satellite cells in muscles from the caveolin 3-deficient transgenic mice was reduced compared with that in the wild-type mice, accompanied by a reduction in myofiber size (Figure 6a ). Because the number of satellite cells in skeletal muscle is known to reduce with age, 31 we counted the number of satellite cells per 100 myofibers or per 100 myonuclei from the quadriceps femoris muscles of mice at three time points (6, 10, or 24 weeks of age; n ¼ 7, Figure 6b ). Compared with the wild-type mice, the caveolin 3-deficient transgenic mice showed a significant reduction in the number of satellite cells at all time points, not only per 100 myofibers, but also per 100 myonuclei. Thus, satellite cell reduction could contribute to the cellular mechanism leading to muscle atrophy in caveolin 3-deficient mice. Consistently, at 16 weeks of age, we found fewer satellite cells in the quadriceps femoris muscles of CAV3 P104L mice than in wildtype mice (n ¼ 7; Figure 6c and d, left) . Conversely, Ki26894 increased the numbers of satellite cells in both caveolin 3-deficient mice and wild-type mice (n ¼ 7; Figure 6c and d, right). These findings were confirmed using another M-cadherin antibody (n ¼ 7; Supplementary Figure 7) . TbRI kinase inhibitors thus increased resident stem cells in both caveolin 3-deficient and normal adult muscle.
Caveolin 1, another isoform of caveolins, was reported to be expressed in M-cadherin-positive satellite cells. 32 To confirm this finding, we stained single myofibers isolated from the EDL muscles of wild-type mice. Because the above two anti-M-cadherin antibodies used in histochemistry showed weak immunoreactivities on satellite cells attached to isolated single myofibers (data not shown), we used an antibody against Pax7, another marker of satellite cells. An anticaveolin-1 antibody stained the regions surrounding Pax-7-positive mononucleated cell attached to a single myofiber from wild-type mice (Supplementary Figure 7b) . Double immunostaining for caveolin 1 and caveolin 3 showed caveolin 1-positive cells located outside of the caveolin 3-positive sarcolemma, confirming the report that caveolin 1 is expressed in the cytoplasm and/or the plasma membrane of satellite cells, whereas caveolin 3 is expressed in the sarcolemma 32 ( Supplementary Figures 7c and 8 ). Using the antibody against caveolin 1, we analyzed satellite cells attached to isolated single myofiber from CAV3 P104L and wild-type mice fed with or without Ki26894 (Figure 6e ). Single myofiber isolated from muscles of CAV3 P104L mice had a reduced number of caveolin 1-positive satellite cells, compared with that of wild-type mice. Ki treatment appeared to alleviate the reduced number of satellite cells and the reduced size of myofiber in CAV3 P104L mice. Quantitative analyses revealed that the numbers of satellite cells per 100 myofibers significantly increased following Ki treatment in isolated myofibers from both lines of mice (n ¼ 7).
DISCUSSION
A growing number of molecules have recently been demonstrated to participate in the molecular mechanisms leading to skeletal muscle atrophy. However, no effective pharmacological intervention is currently available to improve muscle atrophy, except oral steroids, which are of limited efficacy. 3, 4 Small-molecular inhibitors targeting membrane receptor tyrosine or serine/threonine kinases have been highlighted, and in part, are clinically available as molecular-targeting agents for cancer therapy. 33 In the present study, using such an inhibitor of TbRI kinase as an optimal probe, we found that the decrease in muscle precursor satellite cells and impairment of myoblast differentiation that accompanied activation of the TGF-b signaling pathway led to muscular atrophy in a caveolin 3-deficient mouse model. By suppression of multiple anti-myogenic TGF-b signals, oral small-molecule TbRI inhibitors could become an alternative, rationally designed, molecular-targeting agent for treating muscular atrophy in various clinical settings besides caveolin 3 deficiency. We revealed that the three TbRI kinase inhibitors tested suppressed the intracellular signals of TGF-b1, activin, and myostatin in A204 human rhabdomyosarcoma cells and HEK293 embryonic kidney cells. However, the inhibition profile of one inhibitor, Ki26894, against the TGF-b1 and activin signal, differed between A204 human rhabdomyosarcoma cells and HEK293 embryonic kidney cells. Previous studies have shown that individual TbRI kinase inhibitors have different half-maximal inhibitory concentration values or different dissociation constant values for each receptor. 12, 19, 20 Such an inhibition profile may be due to pharmacological differences between each compound, as well as differences in receptor expression in the assayed cells. Similarly to the results of A204 cells, Ki26894 broadly suppressed the upregulation of p21 induced by myostatin, activin, and TGF-b1 in HaCaT cells. These results suggest that TbRI kinase inhibitors can suppress multiple intracellular TGF-b signaling pathways at their membrane receptor levels.
We also demonstrated that Ki26894 enhanced C2C12 myoblast fusion and differentiation into myotubes under low-serum conditions. Previous studies showed that myostatin, activin, or TGF-b1 impaired myogenic differentiation in cultured myogenic cells from several species. 27, [34] [35] [36] Using an efficient retroviral gene expression system, we confirmed that these three molecules independently suppressed mouse C2C12 myoblast differentiation. Conversely, the addition of Ki26894 almost completely restored the myotube formation that was impaired by the TGF-b family members. Taken together, Ki26894 enhances myoblast differentiation into myotubes in vitro by suppressing the multiple intracellular anti-myogenic TGF-b signaling pathways. Ki26894 similarly restored the impaired C2C12 myoblast differentiation induced by forced expression of the P104L mutant caveolin 3.
Consistent with our in-vitro results, oral administration of Ki26894 increased myofiber size and muscle mass in wildtype mice, suggesting enhanced in-vivo myogenesis in normal adult muscles. As expected, Ki26894 prevented muscle atrophy in TGF-b-activated muscles in a P104L mutant caveolin 3 model mouse. Besides myostatin, other members of the TGF-b family have recently been demonstrated to suppress myogenesis in vivo. [37] [38] [39] [40] Transgenic overexpression of follistatin, an inhibitory binding protein of myostatin and activin, enhanced muscularity in mice lacking myostatin. 37 Additionally, conditional deletion of an activin gene increased muscle mass, indicating that activin has a role in suppressing myogenesis in vivo. 38 Moreover, activated intramuscular TGF-b signaling was observed in atrophic muscles from dystrophin-deficient muscular dystrophy patients with impaired muscle regeneration and increased fibrosis. 39, 40 Therefore, Ki26894 may block the intramuscular signaling of activin and TGF-b1, as well as myostatin. Consistent with these in-vitro observations, Ki26894 reduced the increase in the levels of p-Smad2, a TGF-b effector, and reduced upregulation of p21, a target gene of TGF-b family members in treated muscles.
Satellite cells are the resident stem cells of adult skeletal muscles. The caveolin 3-deficient muscles in these mice showed a reduced number of satellite cells in both skeletal muscle sections and isolated single myofibers, compared with wild-type mice. Conversely, the oral TbRI kinase inhibitor restored the reduced number of satellite cells in caveolin 3-deficient atrophic myofibers, in which p21 expression was upregulated. This inhibitor also increased the number of satellite cells in wild-type mouse muscles. TGF-b1-induced p21 upregulation in satellite cells contributed to myofiber hypotrophy in sarcopenia and impaired muscle regeneration in aged mouse muscles. 41 Thus, TbRI kinase inhibitors may increase satellite cells both in atrophic and in normal myofiber by suppressing the TGF-b-p21 axis. However, the effects of myostatin on satellite cells are controversial, because one study revealed an increased number of satellite cells in mice lacking myostatin, 42 whereas another study showed no increase in the number of satellite cells in the same mice. 43 Thus, TbRI kinase inhibitors may increase the number of satellite cells by suppressing members of the TGF-b family other than myostatin, which show similar but not identical intramuscular signaling pathways involving p21. Taken together with the in-vitro results, these observations indicate that oral TbRI inhibitors enhance myogenesis via satellite cells and myoblasts through the caveolin-TGF-b-p21 axis.
In a phase I/II clinical trial, the anti-myostatin neutralizing antibody MYO-029 was reported to dose dependently increase myofiber diameter, but did not improve muscular weakness in patients with muscular dystrophy. 44 Additionally, myostatin-null mice did not exhibit an increase in muscle strength despite an increase in muscle mass. 45 However, administration of Ki26894 enhanced muscle performance in wild-type mice and ameliorated muscular weakness in caveolin 3-deficient mice, as revealed by an increase in grip strength and muscle-specific forces. Thus, pharmacological intervention strategies based on TbRI kinase inhibitors that can suppress the broad TGF-b signaling pathways would be expected to prevent the progression of muscle weakness better than strategies employing other inhibitors that suppress myostatin signaling alone. To evaluate the effect on muscle performance, TbRI kinase inhibitors should be tested in other, larger animal models of muscular atrophy. 46 Long-term administration of Ki26894 had no adverse effects in caveolin 3-deficient mice based on pathological examination of the major organs. Additionally, there were no adverse effects of TbRI kinase inhibitors in animal models of cancers, lung fibrosis, or renal fibrosis. [15] [16] [17] [18] 47, 48 However, it is necessary to define the optimal, but non-toxic dosage of these drugs for the treatment of individual patients with muscular atrophy. In this respect, our ex-vivo myostatin activity assay is a convenient real-time biomonitoring system to determine how myostatin signaling is affected by the administration of In agreement with our first report, 5 two other groups have recently shown that caveolin 3 deficiency causes muscle atrophy through intramuscular TGF-b activation. 29, 49 Caveolin 3-deficient myoblasts formed thin myotubes upon activation of the TGF-b effector, Smad2. 29 Activated Smad2 was also observed in skeletal muscle from patients with muscular dystrophy with generalized lipodystrophy caused by deficiency of cavin, an assembly molecule for caveolin 3. 49 To confirm the novel concept of the caveolin 3-TGF-b-p21 axis in the pathobiology of muscle atrophy, further characterization of both satellite cells and myoblasts will be required in skeletal muscle samples from patients with LGMD1C and cavin 1 deficiency.
